Primary dysmenorrhea. Pain and other conditions associated with female genital organs and menstrual cycle
Conditions
Interventions
Intervention 1: Intervention group: For lavender jelly capsule recipients, the drugs will be delivered to the participants in identical and packaged containers. The drugs will be taken for 5 days (the
the drugs will be delivered to the participants in identical and packaged containers. Placebo capsules will be taken for 5 days (first 5 days of the menstrual cycle) and one 200 mg placebo oral soft c
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 35 Years
Inclusion criteria
Inclusion criteria: Age between 15-35 years Unmarried Experiencing menstrual pain during at least one of the first 3 days of menstrual bleeding for 3 consecutive periods in the past 6 months Primary dysmenorrhea with moderate to severe pain intensity using a pain ruler Regular menstrual cycles with intervals of 21-35 days, menstrual duration of 3-7 days Body mass index less than or equal to 30
Exclusion criteria
Exclusion criteria: Using any herbal remedies or other complementary methods such as heat, massage to treat menstrual pain Symptoms such as burning, itching, and abnormal discharge Smoking Being forced to take medication or follow a special diet History of gynecological or abdominal surgery (including any open surgery or laparotomy and laparoscopy in the pelvic area such as cysts, masses, adhesions) Hypothyroidism or any chronic systemic disease such as diabetes, epilepsy, heart disease, liver disease, and hormonal disorders Presence of tumors and fibroids and history of any pelvic pathology such as PID Taking contraceptive pills for any reason Stressors such as parental separation or death of a relative within the last 6 months History of mental illness such as severe depression and anxiety and treatment with related medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in pain severity (dysmenorrhea). Timepoint: At the baseline (before intervention) and just after completion of the intervention (3 months after beginning the intervention ). Method of measurement: Visual analog scale (VAS).;Changes in menstrual distress score. Timepoint: At the baseline (before intervention) and just after completion of the intervention (3 months after beginning the intervention ). Method of measurement: Menstrual Distress Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in sleep quality score. Timepoint: At the baseline (before intervention) and just after completion of the intervention (3 months after beginning the intervention). Method of measurement: Pittsburgh Sleep Quality Questionnaire.;Changes in life quality score. Timepoint: At the baseline (before intervention) and just after completion of the intervention (3 months after beginning the intervention). Method of measurement: Quality of Life Questionnaire (SF-36).;Side effects of treatment. Timepoint: During treatment. Method of measurement: Side effects checklist.;The rate of satisfaction with medication. Timepoint: End of intervention. Method of measurement: Satisfaction with medication checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzizeh Farshbaf-Khalili
Tabriz University of Medical Sciences
Outcome results
None listed